Thanks for asking the question. I’d also like to know more about this. Somebody from this board must have some knowledge around this subject.

In thinking about it, it seems reasonable that those involved in the trial would know if patients were moved to ventilation, life support, or died. Basically, they’d know if they got worse. But are they able to tie any sort of bloodwork to those patients before unblinding? Because that doesn’t seem as reasonable to me, being unfamiliar with the intricacies of blinded data trial analysis.

I’ve been basing my assumptions of BP, JL, and NP’s confidence in the lab work they’re seeing on the fact that they know what a Leronlimab patient’s bloodwork looks like. But also, maybe they know some patients have progressed significantly, and in a typical Covid > ARDS fashion. Add those things up and the trial outlook would look good. But if they can actually see blood samples of those specific patients, knowing they had progressed, and there’s no evidence of the typical Leronlimab markers in the blood? Well, now things would look great and I’d imagine that would deliver the boatload of confidence to the team that we all feel they are showing.